|
By John S. James
Built to Survive, by AIDS treatment advocates Michael Mooney
and Nelson Vergel, covering anabolic steroids, exercise,
nutrition, and popular supplements (especially for preventing
or treating HIV-related wasting), was published February
2000. Mooney and Vergel are also editors of the MEDIBOLICS
newsletter, www.medibolics.com
The book includes sections on AIDS wasting, BIA
(bioelectrical impedance analysis), testosterone replacement
therapy, different kinds of anabolic steroids, legality of
anabolic steroids in medicine, lipodystrophy and potential
approaches for management, side effects and guidelines for
anabolic steroids, human growth hormone, orthomolecular
nutrition, popular food supplements, various diet plans, food
safety, diarrhea, blood tests to use before starting a
nutritional program, exercise programs, recommended reading,
references, and testimonials.
Built to Survive is published by PoWeR (Program for Wellness
Restoration), a nonprofit organization founded by Nelson
Vergel. The cover price is $24.95, but copies can be ordered
from the Houston Buyers' Club, 1-800-350-2392, for $18.95
+3.95 shipping; the book is also available through
www.amazon.com , which can ship internationally.
Comment:
Built to Survive provides an accessible overview of certain
important therapies, by advocates who have made themselves
experts in this area. Some of the recommendations may be
controversial, and we are not qualified to judge their
medical appropriateness. We suggest this book as a source of
ideas that you may later want to discuss with your physician-
-a discussion which the authors repeatedly urge their readers
to have.
Testosterone Cream is Here—No More Shots!
By John S. James
|
On March 2 the Community Prescription Service, a mail-order
pharmacy associated with POZ magazine and specializing in
HIV, announced that it is selling a compounded testosterone
cream.
This product is not generally available in pharmacies.
("Compounded" means that it is specially prepared by a
pharmacist at the direction of a physician, not a packaged
pharmaceutical product; compounded products do not have to
pass most of the FDA requirements for approval of
pharmaceuticals.)
Topical testosterone has long been available (see Testosterone Cream
and Gel Available; Prices Vary Greatly," AIDS Treatment News #307,
November 20, 1998), but usually only through certain pharmacies which
specialize in compounding.
|
Related Articles from the GayToday Archive:
The Impotence Pill: New Promises of Penile Erections Unhindered
Medical Marijuana:New Treatment Uses & Old Government Abuses
Tai Chi: How Meditative Exercises Help
Related Sites:
AIDS Treatment News
Built to Survive
GayToday does not endorse related sites.
|
With the CPS product, the physician specifies the starting
dose per application, and the cream is made up accordingly.
According to CPS, for most people, an appropriate starting
dose is 12.5 mg of testosterone per application. The same
controlled-substance regulations apply to topical
testosterone as to the injected or patch forms of the drug.
For more information about this testosterone cream, call CPS
at 800-842-0502.
Note: On February 29 Unimed Pharmaceuticals, Inc. announced
that the FDA had approved its AndroGel(TM) 1% testosterone
gel "for replacement therapy in males for conditions
associated with a deficiency or absence of endogenous
testosterone"--the first time the FDA has approved such a
product. However, AndroGel is not expected to be widely
available in pharmacies until mid summer. Apparently AndroGel
will deliver a somewhat higher dose of testosterone than the
CPS cream.
Comment: We expect that the main practical difference between
the products is that the AndroGel will be much more expensive.
AIDS Treatment News
Published twice monthly
Subscription and Editorial Office:
P.O. Box 411256
San Francisco, CA 94141
800/TREAT-1-2 toll-free U.S. and Canada
415/255-0588 regular office number
Fax: 415/255-4659
E-mail: aidsnews@aidsnews.org
Editor and Publisher: John S. James
Associate Editor: Tadd T. Tobias
Reader Services: Tom Fontaine and Denny Smith
Operations Manager: Danalan Richard Copeland
Statement of Purpose:
AIDS Treatment News reports on experimental and standard treatments, especially those available now. We interview physicians, scientists, other health professionals, and persons with AIDS or HIV; we also collect information from meetings and conferences, medical journals, and computer databases. Long-term survivors have usually tried many different treatments, and found combinations which work for them. AIDS Treatment News does not recommend particular therapies, but seeks to increase the options available.
Subscription Information: Call 800/TREAT-1-2 Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks.
ISSN # 1052-4207
Copyright 2000 by John S. James.
|
